Cannara Biotech Company Insiders

Cannara Biotech Management Team Effectiveness

The company has return on total asset (ROA) of 0.0378 % which means that it generated a profit of $0.0378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0678 %, meaning that it generated $0.0678 on every $100 dollars invested by stockholders. Cannara Biotech's management efficiency ratios could be used to measure how well Cannara Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.05 in 2024. Return On Capital Employed is likely to climb to 0.09 in 2024. At this time, Cannara Biotech's Intangible Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to climb to 0.05 in 2024, whereas Net Tangible Assets are likely to drop slightly above 50.7 M in 2024. Net Income Applicable To Common Shares is likely to climb to about 2.8 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 77.2 M in 2024.

Cannara Biotech Workforce Comparison

Cannara Biotech Profit Margins

The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.

Cannara Biotech Benchmark Summation

Cannara Biotech Notable Stakeholders

The success or failure of an entity such as Cannara Biotech often depends on how effective the management is. Cannara Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cannara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cannara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Cannara Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cannara Biotech. Check Cannara Biotech's Beneish M Score to see the likelihood of Cannara Biotech's management manipulating its earnings.

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.